Solid-phase synthesis of dysidiolide-derived protein phosphatase inhibitors.
Biologically active natural products can be regarded as evolutionary selected and biologically validated starting points in structural space for the development of compound libraries. For libraries designed and synthesized around a given natural product, a higher hit rate and the identification of biologically relevant hits can be expected, justifying a probably higher investment in the development of the corresponding syntheses. This approach requires the development of complex multistep reaction sequences on the solid phase. Employing the protein phosphatase Cdc25 inhibitor dysidiolide as an example, we demonstrate that this goal can be achieved successfully. The reaction sequences developed led to dysidiolide analogues in overall 8-12 linear steps with the longest sequence on the solid support amounting to up to 11 sequential transformations. The desired products were obtained in overall yields ranging from 6% to 27% and in multimilligram amounts starting from 100 mg of resin. The transformations applied include a variety of very different reaction types widely used in organic synthesis (i.e., an asymmetric cycloaddition employing a removable chiral auxiliary, different organometallic transformations, olefination reactions, different oxidation reactions, acidic hydrolyses, and a nucleophilic substitution). Biological investigation of the eight dysidiolide analogues synthesized showed that they inhibit Cdc25C in the low micromolar range with the IC(50) value varying by a factor of 20 and that they display considerable and differing biological activities in cytotoxicity assays employing different cancer cell lines.
Brohm
Dirk
D
Max-Planck-Institut für molekulare Physiologie, Abteilung Chemische Biologie, Otto-Hahn-Strasse 11, D-44227 Dortmund, Germany.
Philippe
Nicolas
N
Metzger
Susanne
S
Bhargava
Ajay
A
Müller
Oliver
O
Lieb
Folker
F
Waldmann
Herbert
H
D015107:4-Butyrolactone / Q000031:analogs & derivatives* / Q000138:chemical synthesis* / Q000494:pharmacology; D002625:Chemistry, Organic / Q000379:methods; D003432:Cross-Linking Reagents / Q000737:chemistry; D004791:Enzyme Inhibitors / Q000138:chemical synthesis*; D012717:Sesquiterpenes / Q000138:chemical synthesis / Q000494:pharmacology; D012996:Solutions; D020687:cdc25 Phosphatases / Q000037:antagonists & inhibitors*
D003432:Cross-Linking Reagents; D004791:Enzyme Inhibitors; D012717:Sesquiterpenes; D012996:Solutions; D020687:cdc25 Phosphatases; C121906:dysidiolide; D015107:4-Butyrolactone